Phase 2
Completed N=100
Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Source: ClinicalTrials.gov NCT00971204 ↗
Enrolled (actual)
100
Serious AEs
16.3%
Results posted
Jul 2016
Primary outcomePrimary: Freedom From Recurrence of Atrial Fibrillation — 50 successful participants
Summary
This is a demonstration of safety and efficacy of the ablation for pulmonary vein isolation in the treatment of paroxysmal atrial fibrillation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Freedom From Recurrence of Atrial Fibrillation |
50 | — |
Eligibility Criteria
Inclusion Criteria
- 18 to 70 years
- paroxysmal atrial fibrillation
- failure of at least one AAD
- others
Exclusion Criteria
- overall good health as established by multiple criteria
Data sourced from ClinicalTrials.gov (NCT00971204). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.